Myelodysplasia and autoimmunity

Current Opinion in Rheumatology

Volumn 24, Issue 1, 2012, Pages 97-102

  Giannouli, Stavroula ^a   Kanellopoulou, Theoni ^a   Voulgarelis, Michael ^b  

^a Department of Internal Medicine ^*  (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Apoptosis; Autoimmunity; Cytokines; Interferon regulatory factor 1; Myelodysplasia

Indexed keywords

APOPTOSIS; AUTOIMMUNITY; BONE MARROW SUPPRESSION; CLINICAL FEATURE; CYTOKINE PRODUCTION; CYTOPENIA; DISEASE COURSE; EFFECTOR CELL; HEMATOPOIETIC STEM CELL; HUMAN; LEUKEMIA; MACROPHAGE; MYELODYSPLASTIC SYNDROME; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRELEUKEMIA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T LYMPHOCYTE;

APOPTOSIS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 82955203695     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32834db4ee     Document Type: Review

References (58)

1. Albitar M, Manshouri T, Shen Y, et al. Myelodysplastic syndrome is not merely 'preleukemia'. Blood 2002; 100:791-798. (Pubitemid 34832603)
2. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood 2009; 114:937-951.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997; 89:2079- 2088; Erratum in: Blood 1998; 91:1100. (Pubitemid 27132124)
4. Voulgarelis M, Giannouli S, Ritis K, Tzioufas AG. Myelodysplasia- associated autoimmunity: Clinical and pathophysiologic concepts. Eur J Clin Invest 2004; 34:690-700. (Pubitemid 39423027)
5. Enright H, Jacob HS, Vercellotti G, et al. Paraneoplastic autoimmune phenomena in patients with myelodysplastic syndromes: Response to immunosuppressive therapy. Br J Haematol 1995; 91:403-408.
6. Hamblin TJ. Immunological abnormalities in myelodysplastic syndromes. Semin Hematol 1996; 33:150-162. (Pubitemid 26128722)
7. Economopoulos T, Economidou J, Giannopoulos G, et al. Immune abnormalities in myelodysplastic syndromes. J Clin Pathol 1985; 38:908-911. (Pubitemid 15249708)
8. Giannouli S, Voulgarelis M, Zintzaras E, et al. Autoimmune phenomena in myelodysplastic syndromes: A 4-yr prospective study. Rheumatology (Oxford) 2004; 43:626-632. (Pubitemid 38628195)
9. Molldrem JJ, Leifer E, Bahceci E, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002; 137:156-163. (Pubitemid 34827511)
10. Saunthararajah Y, Nakamura R, Wesley R, et al. A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome. Blood 2003; 102:3025-3027. (Pubitemid 37248879)
11. Yoshida Y. Hypothesis: Apoptosis may be the mechanism responsible for the premature intramedullary cell death in the myelodysplastic syndrome. Leukemia 1993; 7:144-146. (Pubitemid 23048933)
12. Raza A, Gezer S, Mundle S, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995; 86:268-276.
13. Hellström-Lindberg E, Kanter-Lewensohn L, Ost A. Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin. Leuk Res 1997; 21:415-425. (Pubitemid 27308236)
14. Rajapaksa R, Ginzton N, Rott LS, Greenberg PL. Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood 1996; 88:4275-4287. (Pubitemid 26399175)
15. Parker JE, Mufti GJ. Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. Br J Haematol 1998; 101:220-230. (Pubitemid 28261106)
16. Raza A, Gregory SA, Preisler HD. The myelodysplastic syndromes in 1996: Complex stem cell disorders confounded by dual actions of cytokines. Leuk Res 1996; 20:881-890. (Pubitemid 27042321)
17. Josefsen D, Myklebust JH, Lynch DH, et al. Fas ligand promotes cell survival of immature human bone marrow CD34+CD38- hematopoietic progenitor cells by suppressing apoptosis. Exp Hematol 1999; 27:1451-1459. (Pubitemid 29409464)
18. Mundle SD, Mativi BY, Bagai K, et al. Spontaneous down-regulation of Fas-associated phosphatase-1 may contribute to excessive apoptosis in myelodysplastic marrows. Int J Hematol 1999; 70:83-90.
19. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5q- syndrome. Nat Med 2010; 16:59-66.
20. Sloand EM, Pfannes L, Chen G, et al. CD34 cells from patients with trisomy 8 myelodysplastic syndrome (MDS) express early apoptotic markers but avoid programmed cell death by up-regulation of antiapoptotic proteins. Blood 2007; 109:2399-2405. (Pubitemid 46425880)
21. Maurer AB, Ganser A, Buhl R, et al. Restoration of impaired cytokine secretion from monocytes of patients with myelodysplastic syndromes after in vivo treatment with GM-CSF or IL-3. Leukemia 1993; 7:1728-1733. (Pubitemid 23347288)
22. Fontenay-Roupie M, Bouscary D, Guesnu M, et al. Ineffective erythropoiesis in myelodysplastic syndromes: Correlation with Fas expression but not with lack of erythropoietin receptor signal transduction. Br J Haematol 1999; 106: 464-473. (Pubitemid 29450673)
23. Mundle SD, Reza S, Ali A, et al. Correlation of tumor necrosis factor alpha (TNF alpha) with high Caspase 3-like activity in myelodysplastic syndromes. Cancer Lett 1999; 140:201-207. (Pubitemid 29251332)
24. Sawanobori M, Yamaguchi S, Hasegawa M, et al. Expression of TNF receptors and related signalling molecules in the bone marrow from patients with myelodysplastic syndromes. Leuk Res 2003; 27:583-591. (Pubitemid 36398093)
25. Stirewalt DL, Mhyre AJ, Marcondes M, et al. Tumour necrosis factor-induced gene expression in human marrow stroma: Clues to the pathophysiology of MDS? Br J Haematol 2000; 140:444-453.
26. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 1995; 85:3183-3190.
27. Dai CH, Price JO, Brunner T, Krantz SB. Fas ligand is present in human erythroid colony-forming cells and interacts with Fas induced by interferon gamma to produce erythroid cell apoptosis. Blood 1998; 91:1235-1242. (Pubitemid 28086876)
28. Lazarini M, Traina F, Winnischofer SM, et al. Effects of thalidomide on longterm bone marrow cultures from patients with myelodysplastic syndromes: Induction of IL-10 expression in the stromal layers. Leuk Res 2011; 35:1102-1107.
29. Boula A, Voulgarelis M, Giannouli S, et al. Effect of cA2 antitumor necrosis factor-alpha antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res 2006; 12:3099-3108. (Pubitemid 43837357)
30. Zang DY, Goodwin RG, Loken MR, et al. Expression of tumor necrosis factorrelated apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: Effects on in vitro hemopoiesis. Blood 2001; 98:3058-3065.
31. Zhou L, Nguyen AN, Sohal D, et al. Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. Blood 2008; 112:3434-3443.
32. Barrett AJ, Sloand E. Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica 2009; 94:449-451.
33. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology? Semin Hematol 2000; 37:15-29. (Pubitemid 30080244)
34. Melenhorst JJ, Eniafe R, Follmann D, et al. Molecular and flow cytometric characterization of the CD4 and CD8 T cell repertoire in patients with myelodysplastic syndrome. Br J Haematol 2002; 119:97-105. (Pubitemid 35176503)
35. Epperson DE, Nakamura R, Saunthararajah Y, et al. Oligoclonal T cell expansion in myelodysplastic syndrome: Evidence for an autoimmune process. Leuk Res 2001; 25:1075-1083. (Pubitemid 33000488)
36. Matsutani T, Yoshioka T, Tsuruta Y, et al. Determination of T-cell receptors of clonal CD8-positive T-cells in myelodysplastic syndrome with erythroid hypoplasia. Leuk Res 2003; 27:305-312. (Pubitemid 36071387)
37. Kook H, Zeng W, Guibin C, et al. Increased cytotoxic T cells with effector phenotype in aplastic anemia an myelodysplasia. Exp Hematol 2001; 29:1270-1277. (Pubitemid 33033303)
38. Kochenderfer JN, Kobayashi S, Wieder ED, et al. Loss of T-lymphocyte clonal dominance in patients with myelodysplastic syndrome responsive to immunosuppression. Blood 2002; 100:3639-3645. (Pubitemid 35303934)
39. Gao L, Bellantuono I, Elsässer A, et al. Selective elimination of leukemic CD34(+) progenitor cells by cytotoxic T lymphocytes specific for WT1. Blood 2000; 95:2198-2203. (Pubitemid 30167714)
40. Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009; 113:6541-6548.
41. Bettelli E, Oukka M, Kuchroo VK. T(H)-17 cells in the circle of immunity and autoimmunity. Nat Immunol 2007; 8:345-350. (Pubitemid 46745409)
42. Oukka M. Interplay between pathogenic Th17 and regulatory T cells. Ann Rheum Dis 2007; 66 (Suppl 3):iii87-iii90. (Pubitemid 350032642)
43. Kordasti SY, Ingram W, Hayden J, et al. CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS). Blood 2007; 110:847-850. (Pubitemid 47267420)
44. Kordasti SY, Afzali B, Lim Z, et al. IL-17 producing CD4(+) T cells, proinflammatory cytokines and apoptosis are increased in low risk myelodysplastic syndrome. Br J Haematol 2009; 145:64-72.
45. Billström R, Johansson H, Johansson B, Mitelman F. Immune-mediated complications in patients with myelodysplastic syndromes-clinical and cytogenetic features. Eur J Haematol 1995; 55:42-48.
46. Fujita T, Sakakibara J, Sudo Y, et al. Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN-beta gene regulatory elements. EMBO J 1988; 7:3397-3405.
47. Miyamoto M, Fujita T, Kimura Y, et al. Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell 1988; 54:903-913.
48. Willman CL, Sever CE, Pallavicini MG, et al. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259:968-971. (Pubitemid 23080665)
49. Harada H, Kondo T, Ogawa S, et al. Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia; a possible mechanism of tumor suppressor inactivation. Oncogene 1994; 9:3313-3320.
50. Giannouli S, Tzoanopoulos D, Ritis K, et al. Autoimmune manifestations in human myelodysplasia: A positive correlation with interferon regulatory factor- 1 (IRF-1) expression. Ann Rheum Dis 2004; 63:578-582. (Pubitemid 38530204)
51. Starczynowski DT, Karsan A. Innate immune signaling in the myelodysplastic syndromes. Hematol Oncol Clin North Am 2010; 24:343-359. This article highlights the prominent role of the innate immune pathway in regulating hematopoiesis. Increased activation of the innate immune pathway may contribute to dysregulated hematopoiesis, dysplasia, and clonal expansion in myelodysplastic syndromes.
52. Maratheftis CI, Andreakos E, Moutsopoulos HM, Voulgarelis M. Toll-like receptor-4 is up-regulated in hematopoietic progenitor cells and contributes to increased apoptosis in myelodysplastic syndromes. Clin Cancer Res 2007; 13:1154-1160. (Pubitemid 46424055)
53. Maratheftis CI, Giannouli S, Spachidou MP, et al. RNA interference of interferon regulatory factor-1 gene expression in THP-1 cell line leads to Toll-like receptor-4 overexpression/activation as well as up-modulation of annexin-II. Neoplasia 2007; 9:1012-1020. (Pubitemid 350255348)
54. Jung YO, Cho ML, Lee SY, et al. Synergism of toll-like receptor 2 (TLR2), TLR4, and TLR6 ligation on the production of tumor necrosis factor (TNF)- alpha in a spontaneous arthritis animal model of interleukin (IL)-1 receptor antagonist deficient mice. Immunol Lett 2009; 123:138-143.
55. Passweg JR, Giagounidis AA, Simcock M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: A prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/99. J Clin Oncol 2011; 29:303-309.
56. Aggarwal S, van de Loosdrecht AA, Alhan C, et al. Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: Implications for immunotherapy. Br J Haematol 2011; 153:568-581.
57. Appelbaum FR. Immunobiologic therapies for Myelodysplastic syndrome. Best Pract Res Clin Haematol 2004; 17:653-656.
58. Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111:236-242.